![]() In the U.S., the FreeStyle Libre system (10 day) is approved for replacement 2 of blood glucose monitoring (BGM) for adults with diabetes. The FreeStyle Libre system, which first launched in Europe in 2014, with a 14-day wear time, was the first to eliminate the need for fingersticks 10, and is designed to be an easier-to-use 2, streamlined 3 and more affordable system 4 compared with other available CGMs on the market. ![]() "With the new FreeStyle Libre 14 day system, people with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition." "At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. This approval makes Abbott's revolutionary continuous glucose monitor (CGM) the longest lasting self-applied personal glucose sensor available on the market. Food and Drug Administration (FDA) has approved the FreeStyle ® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. doi: 10.2337/cd17-0130.ABBOTT PARK, Ill., J/ PRNewswire/ - Abbott (NYSE: ABT) today announced that the U.S. Freestyle Libre glucose monitoring system. Keys to success: subject profiles, choice of systems, education. The road from intermittently scanned glucose monitoring to hybrid closed-loop systems: part A. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study. Polonsky WH, Fisher L, Schikman CH, et al. ![]() The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. T2D patients who use flash glucose monitoring might expect to achieve significant improvement in HbA1c and glycemic parameters and several associated benefits.įlash glucose sensing Intermittent-scanned continuous interstitial glucose monitoring Type 2 diabetes. Additional benefits associated with flash glucose monitoring versus SMBG include reductions in acute diabetes events, all-cause hospitalizations and hospitalized ketoacidosis episodes improved well-being and decreased disease burden and greater treatment satisfaction. Higher (versus lower) scanning frequency was associated with significantly greater reductions in HbA1c and significant improvements in other measures such as time spent in hypoglycemia, time spent in hyperglycemia, and time in range. Real-world studies in both type 1 diabetes or T2D populations also showed that flash glucose monitoring improved glycemic control. Subsequent RCTs and real-world chart review studies have since shown that flash glucose monitoring significantly reduces HbA1c from baseline. Compared to SMBG, the flash system significantly reduced the time spent in hypoglycemia and frequency of hypoglycemic events, although no significant change was observed in glycosylated hemoglobin (HbA1c) levels. In patients with type 2 diabetes (T2D) receiving insulin therapy, pivotal efficacy data were provided by the 6-month REPLACE randomized controlled trial (RCT) and 6-month extension study. Swiping the reader device over the sensor retrieves stored data and displays current interstitial glucose levels, a glucose trend arrow, and a graph of glucose readings over the preceding 8 h. The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, United Kingdom) consists of a factory-calibrated sensor worn on the back of the arm which measures glucose levels in the interstitial fluid every minute and stores the reading automatically every 15 min. Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy.
0 Comments
Leave a Reply. |